0001104659-20-124470.txt : 20210122 0001104659-20-124470.hdr.sgml : 20210122 20201112165934 ACCESSION NUMBER: 0001104659-20-124470 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 CORRESP 1 filename1.htm

ThinkEquity,

A Division of Fordham Financial Management, Inc

17 State Street, 22nd Floor

New York, New York 10004

November 12, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:

Inhibikase Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-1, as amended (the “Registration Statement”)

File No. 333-240036

Ladies and Gentlemen:

On November 6, 2020, ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”), as representative of the underwriters of the offering, joined in the request of the Company that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so as to permit it to become effective on Tuesday, November 10, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned, on behalf of ThinkEquity, hereby withdraws such request.

	Very truly yours,

	ThinkEquity,
	a division of Fordham Financial Management, Inc.

	By:		/s/ Eric Lord
	Name:		Eric Lord
	Title:		Head of Investment Banking

cc:

Leslie Marlow, Esq.

Patrick J. Egan, Esq.